Membrane-bound complement regulatory proteins (mCRPs) play an important rol
e in the protection of cells from complement-mediated injury. It is now app
arent that malignant tumor cells also express these proteins to escape comp
lement attack. Here, Arko Gorter and Seppo Meri discuss the implications of
complement resistance for the immunotherapeutic treatment of solid tumors
with monoclonal antibodies.